+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Bi-directional Tachycardia Drugs Market Outlook 2028

  • PDF Icon


  • August 2020
  • Region: Global
  • Research Nester Pvt. Ltd
  • ID: 5136581
Ongoing Research Report

In the News
September 2018: Centers for Disease Control and Prevention (CDC) released a report stating that heart attacks, strokes, heart failure and other related conditions are hitting middle-age adults in large number leading 2.2 million hospitalizations and 415,000 deaths in 2016.

Introduction to Bi-directional Tachycardia Drugs

The bi-directional tachycardia drugs are used for the treatment of cardiac disorders in adult patients. Bi-directional tachycardia is a regular ventricular tachyarrhythmia that makes your heart beat more than 100 times per minute. It is characterized by a beat-to-beat alternation of the frontal QRS axis. The bi-directional tachycardia can disrupt normal heart function and can lead to serious complications including heart failure, stroke, sudden cardiac arrest or even death. It is most likely to affect people who smoke, consume excess alcohol, or have a lot of caffeine. In some cases, it’s linked to heart attacks.

Market Size and Forecast

Rising cases of patients with cardiac diseases coupled with the advancements in healthcare as well as improvements in treatment therapies are the significant factors boosting the market growth. The bi-directional tachycardia drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by distribution channel into hospitals, clinics, research laboratories and retail pharmacies. Among these segments, the segment for hospitals is anticipated to hold the leading share in the market on account of wide-scale availability of bi-directional tachycardia drugs used for the patient’s treatment at the hospital only.

Growth Drivers

Increasing Prevalence of Cardiac Disorders Globally to Boost the Market Growth

Rising incidences of cardiovascular disorders across the world and related diseases such as arrhythmia, heart attacks and strokes is the key dynamic factor propelling the growth of bi-directional tachycardia drugs. According to World Health Organization (WHO), in 2016, an estimated 17.9 million people died from cardiovascular diseases (CVDs) which represents 31% of all deaths worldwide. Moreover, growing geriatric population diagnosed with heart diseases and changing lifestyles are other factors are anticipated to significantly expand the bi-directional tachycardia drugs market.

By Region

On the basis of regional analysis, the bi-directional tachycardia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

The market for bi-directional tachycardia drugs in North America is anticipated to hold the largest share in the market on account of presence of leading market players in the region which manufacture and market bi-directional tachycardia drugs. Moreover, growing healthcare expenditure and support from government in implementation of advanced therapeutics coupled with the rise in patients with cardiovascular disorders in the region further increases the product demand. The bi-directional tachycardia drugs market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of developing healthcare infrastructure and growing research activities in the region. Additionally, the prevalence of chronic diseases along with the rise in public awareness about early diagnosis of heart disease like tachycardia, especially in countries such as China, India and Japan further raise the demand for bi-directional tachycardia drugs.

The bi-directional tachycardia drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Please note this is an ongoing research and will be delivered 8-9 working days after order confirmation. The TOC can be also be requested.

Companies Mentioned

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline plc.
  • Merck and Co., Inc.
  • Sanofi
  • Bayer AG
  • Pfizer Inc.
  • Other Notable Players

Please note the number of players as well as the addition/deletion can be done in the final deliverable as per the feasibility